ArticleActa ophthalmologica2026
Multi-site performance of the telemedicine retinopathy of prematurity severity score (tROP-SS).
Article in Acta ophthalmologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aims to evaluate the performance of the telemedicine retinopathy of prematurity severity score (tROP-SS) across all 14 NICUs in the TELEROP cohort against the modified ROP activity score (mROP-ActS).
designRetrospective cohort study. SUBJECTS: The study included 2037 neonates who underwent ROP screening in 14 NICUs via the TELEROP telemedicine network from November 2017 to January 2025.
methodsWe compared the robustness of tROP-SS and mROP-Act systems across all exams.
main outcome measuresThe primary outcomes studied were the ability to return a score in cases responding to treatment, correlation between the two scores and the ability to assess disease directionality.
resultsThe study analysed 192 704 photos from 11 368 ROP exams on 2037 patients. tROP-SS generated scores for 100% of exams, demonstrating significant improvements over mROP-ActS, which scored only 92.3% of all exams (p = 0.0136). All patients who met treatment criteria received treatment in both eyes. Among high-risk and treatment warranted (TW) patients, 100.0% exams had a valid tROP-SS exam compared with only 72.73% and 45.27% with a valid mROP-ActS. Only 20.9% high-risk or TW patients had a valid mROP-ActS across all their exams. Incremental increases in tROP-SS were more strongly related to worsening of disease: OR (95% CI) - 3.37 (2.51-4.53) versus 1.57 (1.46-1.69), both p < 0.0001. tROP-SS also demonstrated improved granularity and accuracy in categorizing patients that would ultimately require treatment (AUC: 0.991 vs. 0.825).
conclusionstROP-SS was retrospectively evaluated across 14 NICUs, proving to be a more robust scoring system compared to mROP-ActS. The findings support continued use of tROP-SS, supplemented by standard screening protocols to ensure no cases of treatment-warranted ROP are missed. Future research may focus on integrating additional parameters to enhance predictive models to improve early ROP detection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.